Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy

Li, Yujing; Ding, Jianxun; Xu, Xiaoding; Shi, Run; Saw, Phei Er; Wang, Junqing; Chung, Shirley; Li, Wenliang; Aljaeid, Bader M.; Lee, Robert J.; Tao, Wei; Teng, Lesheng; Farokhzad, Omid C. und Shi, Jinjun (2020): Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy. In: Nano Letters, Bd. 20, Nr. 7: S. 4857-4863

Abstract

As a hallmark of solid tumors, hypoxia promotes tumor growth, metastasis, and therapeutic resistance by regulating the expression of hypoxia-related genes. Hypoxia also represents a tumor-specific stimulus that has been exploited for the development of bioreductive prodrugs and advanced drug delivery systems. Cell division cycle 20 ( CDC20) functions as an oncogene in tumorigenesis, and we demonstrated the significant upregulation of CDC20 mRNA in the tumor vs paratumor tissues of breast cancer patients and its positive correlation with tumor hypoxia. Herein, a hypoxia-responsive nanoparticle (HRNP) was developed by self-assembly of the 2-nitroimidazole-modified polypeptide and cationic lipid-like compound for delivery of siRNA to specifically target CDC20, a hypoxia-related protumorigenic gene, in breast cancer therapy. The delivery of siCDC20 by HRNPs sufficiently silenced the expression of CDC20 and exhibited potent antitumor efficacy. We expect that this strategy of targeting hypoxia-correlated protumorigenic genes by hypoxia-responsive RNAi nanoparticles may provide a promising approach in cancer therapy.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1530-6984
• Sprache: Englisch